| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.1052 |
| P698 | PubMed publication ID | 11456310 |
| P50 | author | Ichiro Kawachi | Q16770280 |
| Walter C. Willett | Q1133904 | ||
| Graham Colditz | Q5592728 | ||
| Frank E. Speizer | Q28114643 | ||
| Alberto Ascherio | Q67175546 | ||
| P2093 | author name string | M A Hernán | |
| S M Zhang | |||
| P2860 | cites work | Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 |
| Aetiology of Parkinson's disease | Q28261357 | ||
| Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects | Q28327704 | ||
| Reproducibility and validity of a semiquantitative food frequency questionnaire | Q29615669 | ||
| Association of coffee and caffeine intake with the risk of Parkinson disease | Q34508881 | ||
| Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden | Q38547787 | ||
| Caffeine and the antiparkinsonian response to levodopa or piribedil | Q39739381 | ||
| Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism | Q40003519 | ||
| Addiction to nicotine is due to high intrinsic levels of dopamine | Q41109812 | ||
| The Nurses' Health Study: 20-year contribution to the understanding of health among women | Q41378639 | ||
| Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. | Q44118324 | ||
| Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study | Q45332787 | ||
| Reasons for changing caffeinated coffee consumption: the Rancho Bernardo Study | Q46639364 | ||
| Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study | Q46977345 | ||
| Caffeine mimics dopamine receptor agonists without stimulation of dopamine receptors | Q48334989 | ||
| Smoking and Parkinson's disease: a case-control study in Germany. | Q50953639 | ||
| Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. | Q52221249 | ||
| Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire | Q57982167 | ||
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 56-63 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Prospective study of caffeine consumption and risk of Parkinson's disease in men and women | |
| P478 | volume | 50 |
| Q44072123 | 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism |
| Q43089180 | A diet for dopaminergic neurons? |
| Q53097591 | A meta-analysis of tea drinking and risk of Parkinson's disease. |
| Q28393626 | A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort |
| Q40473068 | A prospective study of alcoholism and the risk of Parkinson's disease. |
| Q35450495 | A prospective study of bowel movement frequency and risk of Parkinson's disease |
| Q48034789 | A reduction in DNA damage in neural tissue and peripheral blood of old mice treated with caffeine. |
| Q37350053 | A systematic review of nutritional risk factors of Parkinson's disease |
| Q36905601 | Acrylamide in coffee: review of progress in analysis, formation and level reduction. |
| Q92583755 | Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease |
| Q36973390 | Adenosine A(2A) receptors in Parkinson's disease treatment |
| Q28477288 | Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients |
| Q48277907 | Adenosine A1 receptors measured with 11 C-MPDX PET in early Parkinson's disease. |
| Q40358428 | Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity. |
| Q38010070 | Adenosine A2A antagonists in Parkinson's disease: what's next? |
| Q35592790 | Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease |
| Q44324438 | Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats |
| Q33811654 | Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease |
| Q36172464 | Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience |
| Q35799088 | Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease |
| Q48380876 | Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. |
| Q36083482 | Adenosine and brain function |
| Q29346491 | Adenosine receptors as drug targets--what are the challenges? |
| Q24632095 | Adenosine receptors as therapeutic targets |
| Q35063214 | Adenosine receptors in the nervous system: pathophysiological implications. |
| Q24634273 | Adenosine signaling and function in glial cells |
| Q37719729 | Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. |
| Q40050523 | Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men. |
| Q36543263 | Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women |
| Q40571222 | Alcohol consumption and the incidence of Parkinson's disease |
| Q36165052 | An exploratory analysis on gene-environment interactions for Parkinson disease |
| Q34017691 | An exploratory study on CLU, CR1 and PICALM and Parkinson disease |
| Q26866338 | Antioxidant and Antiradical Activity of Coffee |
| Q34974866 | Antioxidants as treatment for neurodegenerative disorders |
| Q34501906 | Association of Coffee Consumption With Total and Cause-Specific Mortality in 3 Large Prospective Cohorts |
| Q34432190 | Association of coffee drinking with all-cause mortality: a systematic review and meta-analysis |
| Q46561073 | Association of serum caffeine concentrations with blood lipids in caffeine-drug users and nonusers - results of German National Health Surveys from 1984 to 1999. |
| Q35597397 | Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study |
| Q34168266 | Astrocytes and Therapeutics for Parkinson's Disease |
| Q24633444 | Available and emerging treatments for Parkinson's disease: a review |
| Q28080872 | Beneficial and detrimental role of adenosine signaling in diseases and therapy |
| Q57127544 | Blood donations, iron stores, and risk of Parkinson's disease |
| Q90544162 | Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest |
| Q36070544 | Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine |
| Q33745754 | Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice |
| Q30432945 | Caffeine and progression of Parkinson disease |
| Q36560201 | Caffeine and risk of Parkinson's disease in a large cohort of men and women |
| Q34002675 | Caffeine attenuates lipopolysaccharide-induced neuroinflammation. |
| Q35001194 | Caffeine consumption and the risk of primary open-angle glaucoma: a prospective cohort study |
| Q37581186 | Caffeine extends life span, improves healthspan, and delays age-associated pathology in Caenorhabditis elegans |
| Q50262567 | Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study |
| Q36019163 | Caffeine intake, smoking, and risk of Parkinson disease in men and women |
| Q36954618 | Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum |
| Q33828847 | Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration |
| Q34905120 | Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases |
| Q43962590 | Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice |
| Q35920604 | Caffeine, coffee, and tea intake and urinary estrogens and estrogen metabolites in premenopausal women |
| Q38893103 | Caffeine, creatine, GRIN2A and Parkinson's disease progression |
| Q34126927 | Calcium channel blocker use and risk of Parkinson's disease |
| Q97420297 | Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? |
| Q36250876 | Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold. |
| Q54917713 | Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum. |
| Q33954408 | Chronic caffeine ingestion causes microglia activation, but not proliferation in the healthy brain |
| Q37435620 | Cigarette smoking and completed suicide: results from 3 prospective cohorts of American adults |
| Q57750580 | Cigarette smoking and the incidence of Parkinson's disease in two prospective studies |
| Q39940475 | Cigarette smoking, coffee intake and alcohol consumption preceding Parkinson's disease: a case-control study |
| Q56839380 | Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role |
| Q36886788 | Coffee and Liver Disease |
| Q47195821 | Coffee consumption and disease correlations |
| Q49109682 | Coffee consumption may influence hippocampal volume in young women |
| Q40790044 | Coffee consumption protects against progression in liver cirrhosis and increases long-term survival after liver transplantation |
| Q50908831 | Coffee extract and caffeine enhance the heat shock response and promote proteostasis in an HSF-1-dependent manner in Caenorhabditis elegans. |
| Q26852456 | Coffee, Genetic Variants, and Parkinson's Disease: Gene-Environment Interactions |
| Q34425199 | Coffee, caffeine, and risk of completed suicide: results from three prospective cohorts of American adults |
| Q36011013 | Coffee, caffeine-related genes, and Parkinson's disease: a case-control study |
| Q34146889 | Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies |
| Q48566146 | Cognitive and Neuropsychiatric Features of Early Parkinson's Disease |
| Q91881378 | Connecting environmental exposure and neurodegeneration using cheminformatics and high resolution mass spectrometry: potential and challenges |
| Q33603777 | Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology |
| Q24653226 | Consumption of dairy products and risk of Parkinson's disease |
| Q37352640 | Consumption of dietary caffeine and coffee in physically active populations: physiological interactions |
| Q28214322 | Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease |
| Q39381016 | DCTN1-related neurodegeneration: Perry syndrome and beyond |
| Q37096777 | Declining quality of life in Parkinson disease before and after diagnosis |
| Q36632177 | Diet, urate, and Parkinson's disease risk in men. |
| Q86048543 | Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece |
| Q28085390 | Dietary factors in the etiology of Parkinson's disease |
| Q37305887 | Dietary iron intake and risk of Parkinson's disease |
| Q47851272 | Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. |
| Q48496249 | Differential effects of age on human striatal adenosine A₁ and A(2A) receptors. |
| Q37044339 | Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study |
| Q37677179 | Differential regulation of microglial motility by ATP/ADP and adenosine |
| Q35781148 | Disease modification in Parkinson's disease |
| Q29248297 | Disease-toxicant interactions in Parkinson's disease neuropathology |
| Q47628064 | Distinct sensitivity to caffeine-induced insomnia related to age. |
| Q64075420 | Dorsal Striatum Dopamine Levels Fluctuate Across the Sleep-Wake Cycle and Respond to Salient Stimuli in Mice |
| Q34359390 | Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease |
| Q37358676 | Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease |
| Q35635814 | Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats |
| Q46041489 | Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum |
| Q64119904 | Effects of Enteric Environmental Modification by Coffee Components on Neurodegeneration in Rotenone-Treated Mice |
| Q36882447 | Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease |
| Q37289669 | Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model |
| Q77599277 | Epidemiological studies: risk factors session IV summary and research needs |
| Q29614901 | Epidemiology of Parkinson's disease |
| Q82029321 | Epidemiology of Parkinson's disease |
| Q36660192 | Erectile function and risk of Parkinson's disease |
| Q28078276 | Essential Roles of Natural Products and Gaseous Mediators on Neuronal Cell Death or Survival |
| Q36172639 | Estimated life expectancy of Parkinson's patients compared with the UK population |
| Q46890609 | Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. |
| Q35141458 | Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? |
| Q48534978 | Extended exposure to sugar and/or caffeine produces distinct behavioral and neurochemical profiles in the orbitofrontal cortex of rats: Implications for neural function. |
| Q37393477 | Family history of melanoma and Parkinson disease risk |
| Q34437648 | Formulations of hormone therapy and risk of Parkinson's disease |
| Q90321601 | Functional and Neuroprotective Role of Striatal Adenosine A2A Receptor Heterotetramers |
| Q92620973 | Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson's disease |
| Q37091302 | Genetic determinants of hair color and Parkinson's disease risk |
| Q37037053 | Genetics of Parkinson disease |
| Q34119748 | Genetics of caffeine consumption and responses to caffeine |
| Q34898429 | Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling |
| Q36352038 | Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM |
| Q35872348 | Habitual intake of dietary flavonoids and risk of Parkinson disease |
| Q38772021 | Health benefits of methylxanthines in neurodegenerative diseases |
| Q38882782 | How does adenosine control neuronal dysfunction and neurodegeneration? |
| Q36667311 | Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease |
| Q50125651 | Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease |
| Q38150457 | Impact of coffee on liver diseases: a systematic review |
| Q37022293 | Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans |
| Q52148359 | Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent. |
| Q36227210 | Influence of coffee drinking and cigarette smoking on the risk of primary late onset blepharospasm: evidence from a multicentre case control study |
| Q36108811 | Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: Results from five cohort studies |
| Q48520930 | Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk |
| Q53071535 | Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice. |
| Q36196764 | Is coffee a functional food? |
| Q40473065 | Life style risks of Parkinson's disease: association between decreased water intake and constipation. |
| Q35580323 | Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study |
| Q34802076 | MPTP: insights into parkinsonian neurodegeneration |
| Q28387116 | Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007 |
| Q37791062 | Methylxanthines and Human Health: Epidemiological and Experimental Evidence |
| Q37791041 | Methylxanthines and Ryanodine Receptor Channels |
| Q34615473 | Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness |
| Q34842250 | Modulators of nucleoside metabolism in the therapy of brain diseases. |
| Q26750581 | Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview |
| Q47602688 | Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice |
| Q36723079 | Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors. |
| Q24604052 | Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease |
| Q38903349 | Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone. |
| Q24630237 | Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease |
| Q37775509 | Neuroprotective herbs and foods from different traditional medicines and diets. |
| Q33821316 | Neuroproteomics as a promising tool in Parkinson's disease research |
| Q36611507 | Nongenetic causes of Parkinson's disease. |
| Q90321608 | Novel Players in the Aging Synapse: Impact on Cognition |
| Q37627259 | Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. |
| Q37844573 | Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. |
| Q37054896 | Nutrition and the risk for Parkinson's disease: review of the literature |
| Q92641926 | Nutritional Risk Factors, Microbiota and Parkinson's Disease: What Is the Current Evidence? |
| Q48024631 | Nutritional habits, risk, and progression of Parkinson disease |
| Q36854132 | Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease |
| Q34990189 | Parkinson's disease and tea: a quantitative review |
| Q34522327 | Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake |
| Q35614156 | Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa |
| Q37779428 | Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition |
| Q34363409 | Particulate matter and risk of Parkinson disease in a large prospective study of women |
| Q35489240 | Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. |
| Q34674177 | Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors |
| Q36860620 | Pathogenesis of Parkinson's disease: oxidative stress, environmental impact factors and inflammatory processes |
| Q37506492 | Pathogenesis-targeted, disease-modifying therapies in Parkinson disease |
| Q39157893 | Pathological overproduction: the bad side of adenosine. |
| Q35008049 | Pathophysiological roles for purines: adenosine, caffeine and urate |
| Q36660181 | Perceived imbalance and risk of Parkinson's disease |
| Q23909800 | Pesticide/environmental exposures and Parkinson's disease in East Texas |
| Q35643171 | Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity |
| Q51800931 | Plant-Derived Natural Products for Parkinson's Disease Therapy. |
| Q34179611 | Plasma urate and Parkinson's disease in women |
| Q36667290 | Plasma urate and risk of Parkinson's disease |
| Q34044101 | Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women |
| Q37129378 | Potential Role of Caffeine in the Treatment of Parkinson's Disease |
| Q35671020 | Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease |
| Q35182956 | Potential therapeutic properties of green tea polyphenols in Parkinson's disease |
| Q34777609 | Preclinical jockeying on the translational track of adenosine A2A receptors |
| Q34133288 | Prenatal and early life factors and risk of Parkinson's disease |
| Q44283552 | Presynaptic inhibition of synaptic transmission by adenosine in rat subthalamic nucleus in vitro |
| Q89639221 | Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist |
| Q57303276 | Prospective study of coffee consumption and risk of Parkinson's disease |
| Q36100697 | Prospective study of statin use and risk of Parkinson disease |
| Q36844881 | Purinergic receptors as potential therapeutic targets in Alzheimer's disease |
| Q48158501 | Rapid test for the determination of total phenolic content in brewed-filtered coffee using colorimetric paper |
| Q37362137 | Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease |
| Q35044966 | Restless legs syndrome and Parkinson's disease in men |
| Q54540450 | Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. |
| Q49336936 | Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease |
| Q43444568 | Smoking and Parkinson's disease |
| Q34917908 | Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality |
| Q61444123 | State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease |
| Q26740559 | Structure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the Drawbacks |
| Q35493114 | Stuck at the bench: Potential natural neuroprotective compounds for concussion |
| Q26859305 | Successful therapies for Alzheimer's disease: why so many in animal models and none in humans? |
| Q51944364 | Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. |
| Q35151652 | Sweetened beverages, coffee, and tea and depression risk among older US adults |
| Q60309448 | Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB |
| Q42506560 | Synthesis and Characterization of a New Bivalent Ligand Combining Caffeine and Docosahexaenoic Acid. |
| Q47137101 | Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches |
| Q37302453 | Targets for neuroprotection in Parkinson's disease |
| Q38532720 | Tea Polyphenols in Parkinson's Disease |
| Q36663122 | Telomere length and risk of Parkinson's disease |
| Q60938826 | The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases |
| Q33729422 | The Safety of Ingested Caffeine: A Comprehensive Review |
| Q38914196 | The best medicine? The influence of physical activity and inactivity on Parkinson's disease |
| Q40811972 | The coffee paradox in stroke: Increased consumption linked with fewer strokes |
| Q36010835 | The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2 |
| Q28293887 | The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat |
| Q56700734 | The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat |
| Q37622710 | The emerging role of nutrition in Parkinson's disease |
| Q35206992 | The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? |
| Q30244421 | The epidemiology of Parkinson's disease: risk factors and prevention |
| Q44464146 | The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. |
| Q21129436 | The promise of neuroprotective agents in Parkinson's disease |
| Q36131077 | The role of ATP and adenosine in the brain under normoxic and ischemic conditions |
| Q48196338 | Transient parkinsonism in bilateral striopallidodentate calcinosis |
| Q37200611 | Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A 2A receptor knockout mice with microarray profiling |
| Q24594751 | Use of ibuprofen and risk of Parkinson disease |
| Q79290509 | Use of nutritional supplements in patients with Parkinson's disease: a cause for concern? |
| Q92503111 | Validation of an LC-MS/MS Method for the Quantification of Caffeine and Theobromine Using Non-Matched Matrix Calibration Curve |
| Q90671795 | What and How Can Physical Activity Prevention Function on Parkinson's Disease? |
Search more.